Drug Approval | February 01, 2024
Orchid Pharma's Exblifeb granted EMA approval
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Tritan Renew, which is made with 50% certified recycled content derived from hard-to-recycle waste, performs like virgin-quality material
Combines biocompatibility, heat-resistance, transparency and durability
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
The company will be preferred business partner for VPPL in terms of sourcing and supplying key raw materials
The company intends to respond to the two minor observations within the stipulated time
The new campus has been designed as an employee-centred experience and ecosystem zone
An accomplished R&D leader and champion of the application of AI to drug discovery
Subscribe To Our Newsletter & Stay Updated
